Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants-Reference-Cited by-同舟云学术

Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants

Published:2019-06-19 Issue:6 Volume:154 Page:e190484
ISSN:2168-6254
Container-title:JAMA Surgery
language:en
Short-container-title:JAMA Surg

Author:

Dimitrakopoulos Christos¹²,Vrugt Bart³,Flury Renata⁴,Schraml Peter³,Knippschild Uwe⁵,Wild Peter³⁶,Hoerstrup Simon⁷,Henne-Bruns Doris⁵,Wuerl Peter⁸,Graf Rolf⁹,Breitenstein Stefan¹⁰,Bond Gareth¹¹,Beerenwinkel Niko¹²,Grochola Lukasz Filip⁷¹⁰

Affiliation:

1. Computational Biology Group, Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland

2. Swiss Institute of Bioinformatics, Basel, Switzerland

3. Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland

4. Institute for Pathology, Cantonal Hospital of Winterthur, Winterthur, Switzerland

5. Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany

6. Senckenberg Institute for Pathology, Goethe University Hospital Frankfurt, Frankfurt, Germany

7. Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland

8. Department of General, Visceral and Thoracic Surgery, Klinikum Dessau, Dessau, Germany

9. Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland

10. Department of Visceral and Thoracic Surgery, Cantonal Hospital of Winterthur, Winterthur, Switzerland

11. Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Surgery

Link

http:///jamasurgery/article-pdf/154/6/e190484/17673881/jamasurgery_dimitrakopoulos_2019_oi_190010.pdf

Reference50 articles.

1. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia?;Lennon;Cancer Res,2014

2. Pancreatic adenocarcinoma.;Ryan;N Engl J Med,2014

3. Approach to patients with pancreatic cancer without detectable metastases.;Heestand;J Clin Oncol,2015

4. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients.;Yekebas;Ann Surg,2008

5. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.;Mueller;Nature,2018

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Predictive Noninvasive Single-Nucleotide Variation–Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study;JMIR Research Protocols;2024-05-13

2. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma;Nature Medicine;2024-01-29

3. Identification of Transcriptomic Signatures of Pancreatic Ductal Adenocarcinoma–Derived Exosomes That Promote Macrophage M2 Polarization and Predict Prognosis: S100A9 Reveals Tumor Progression;Clinical Medicine Insights: Oncology;2024-01

4. Development of a monoclonal antibody to ITPRIPL1 for immunohistochemical diagnosis of non-small cell lung cancers: accuracy and correlation with CD8+ T cell infiltration;Frontiers in Cell and Developmental Biology;2023-12-19

5. A Predictive Noninvasive Single-Nucleotide Variation–Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study (Preprint);2023-10-27